News  ›  Article

Farris LLP: Vancouver's Law Firm


27 December 2007

Hector Mackay-Dunn, Q.C. Speaks on BC Biotech in the Vancouver Sun

In the business section of today’s Vancouver Sun newspaper, Farris Partner, Hector MacKay-Dunn, Q.C. is extensively quoted in an article titled “Ups and downs hit B.C. biotech in 2007” by Gillian Shaw. MacKay-Dunn, a Partner at Farris, is a director and advisor for companies in all sectors including the technology and biotechnology sectors. He has been involved in some of the biggest and most strategic deals in Canada, including Aspreva where he is on the board and where he was the director who delivered the final shareholder vote tally to a recent meeting in which 99 per cent of shareholders approved Aspreva’s sale to the Galenica Group of Switzerland. MacKay-Dunn says, “There is no question that we’ve closed a chapter and started a new chapter in the biotech space in British Columbia with the recent Aspreva sale, the Anormed sale - which was really last year - and QLT announcing it is essentially looking for potential buyers for the company or part of the company.” He went on to say “When you take all that together, and realizing those companies represented the pioneering generation of the industry - and with Aspreva, part of the new generation - they represent the closing of a chapter. But it is not the end of the story, by any means.” For the full story, please click here.

‹ Back